WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. today announced that its partner BeiGene has dosed the first five patients in its first-in-human Phase 1 trial to evaluate BG-68501, a small ...
WALTHAM, Mass., October 01, 2025--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM) today announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation to its clinical stage pan ...
Enzymes that drive cancer growth are already addressed by several drugs, but there’s still room to improve and expand this approach. BeiGene sees opportunity in the lead program of Ensem Therapeutics ...
Ensem Therapeutics, Inc announced that its partner BeiGene has dosed the first five patients in its first-in-human phase 1 trial to evaluate BG-68501, a small molecule cyclin-dependent kinase 2 (CDK2) ...
Ensem Therapeutics, Inc, a pioneering drug discovery and development company to leverage its unique kinetic ensemble platform to advance innovative small molecule precision medicines for oncology, ...
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small ...
Preclinical Data to be Presented at the AACR Annual Meeting Showcasing Ensem’s Advancements in Next-Generation Precision Oncology Ensem Therapeutics, Inc. (ENSEM), a clinical-stage, oncology-focused ...
Nov 21 (Reuters) - BeiGene 6160.HK said on Tuesday it would buy the global license for a cancer therapy that is ready to enter early-stage trial from U.S.-based biotech company Ensem Therapeutics. The ...
"Dr. Kutok is a seasoned executive with the right credentials to guide ENSEM's science into the future," stated Shengfang Jin, Ph.D., President & Chief Executive Officer of ENSEM. "We are excited to ...
Ensem Therapeutics Inc. has gained IND clearance from the FDA for ETX-636, a novel allosteric pan-mutant-selective PI3Kα inhibitor and degrader. A first-in-human trial will begin this quarter. The ...
Ensem Therapeutics highlights novel, potent, and selective oral pan-KRAS and WRN inhibitors with best-in-class potential at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results